CoChat

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

Open access
Nyström, Thomas, Bodegard, Johan, Nathanson, David, Thuresson, Marcus, Norhammar, Anna, Eriksson, Jan W. · 2017 · Diabetes, Obesity and Metabolism
Cited by 84

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Aims: To investigate the association of novel oral glucose‐lowering drugs ( GLDs ), compared with that of insulin, with risk of all‐cause mortality, cardiovascular disease ( CVD ) and severe hypoglycaemia. Methods: During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users of novel oral GLDs , either dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors or sodium‐glucose cotransporter‐2 ( SGLT2 ) inhibitors (only dapagliflozin available in Sweden during the study period), with those initiating insulin as a comparison group, in the Prescribed Drug Register were included and followed in the Patient and Cause of Death Registers. The novel GLD group and insulin group were matched 1:1 using propensity score. Cox regression models were used to estimate risks. Results: Of 37 603 patients, 21 758 were matched 1:1 to novel GLD vs insulin groups, with median follow‐up times of 1.51 years (16 304 patient‐years) and 1.53 years (16 306 patient‐years), respectively. Treatment with novel GLDs was associated with a 44% (hazard ratio [ HR ] 0.56 [95% confidence interval { CI } 0.49‐0.64]), 15% ( HR 0.85 [95% CI 0.73‐0.99]) and 74% (0.26 [95% CI 0.12‐0.57]) lower risk of all‐cause mortality, CVD and hypoglycaemia, respectively, compared with insulin treatment. In separate analyses for the two novel GLDs , dapagliflozin was associated with lower risks of all‐cause mortality and CVD (56% [ HR 0.44, 95% CI 0.28‐0.70] and 49% [ HR 0.51, 95% CI 0.30‐0.86], respectively), while DPP ‐4 inhibitor treatment was associated with lower risk of all‐cause mortality (41% [ HR 0.59, 95% CI 0.51‐0.67]), but not with CVD ( HR 0.87, 95% CI 0.75‐1.01). Conclusions: Novel oral GLD treatment was associated with lower risk of all‐cause mortality, CVD and severe hypoglycaemia compared with insulin treatment. Dapagliflozin was associated with a lower risk of both all‐cause mortality and CVD , whereas DPP ‐4 inhibitor treatment was only associated with lower risk of all‐cause mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12889

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 84

Metadata

Authors
Nyström, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-03-16
Volume
19
Issue
6
Pages
831-841
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2585095576
Cited by
84
References
13
FWCI
9.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.